top of page

Meet the Visionaries Tackling Post-Traumatic Stress Disorder

Current treatments for PTSD include psychotherapy and pharmaceuticals; however, neither are consistently effective.

About two-thirds of people treated with talk therapy do not see their symptoms improve, while a large percentage may experience worsening symptoms.

Evren is focused on providing the best possible care for patients living with PTSD, and our team has extensive experience in research and development of biomedical devices, consulting, entrepreneurship, and medical technology.

In today's investor article, I want to take a moment to introduce you to the leaders who will be making a drug-free solution to PTSD widely available to the millions of sufferers in America who are still seeking treatment.

Weaver Gaines, Chairman and CEO

Weaver Gaines has over 40 years of entrepreneurial, management, and legal experience, including over 25 years as a founder, fund-raiser, and manager of start-up life science companies. Most recently, he was a co-founder and CEO of OBMedical Company, a medical device company that developed and received FDA clearance for an electronic maternal fetal monitor, which was acquired by Philips Healthcare in 2018.

Gaines received a BA from Dartmouth College and a JD from the University of Virginia School of Law and was an Infantry officer who served in Vietnam from 1969-70, with a final rank of Captain.

Neil Euliano, Chief Technology Officer

Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 US patents and has ten more pending. In addition, he has a long history in managing multidisciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research. His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He has been involved in the successful FDA clearance of more than 6 medical devices.

Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.

Kimberly A. Ramsey, Chief Financial Officer

A serial entrepreneur, with 30 years progressive corporate finance and operations experience, Ramsey has played a key role in raising over $100 million, including several successful IPOs. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas. Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida.

Stephanie Warrington, Member of Board of Directors

Ms. Warrington has been an independent consultant since 2014, advising a wide range of early stage medtech and biotech companies in strategic and business planning, investor relations, licensing, product development and building early stage corporate infrastructure. She has over 25 years of experience in the healthcare industry, with the past 15 years being involved in cutting edge startups working to solve difficult healthcare challenges. She was a founder, president and director of TrueMotion Spine, Inc., a Co-founder and VP, Corporate Development for Xhale, Inc., and President of Synogen, Inc. She holds an MBA, an MHA, and a BS in Business Administration from the University of Florida.

Robert V. House, Member of Board of Directors

Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities. He is also a director of Arrevus, Inc. He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books. In addition, he is an adjunct professor at George Mason University. Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology), his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative.

Richard Ferrari, Member of Board of Directors

Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Biotechnology. He has raised over a billion dollars for companies he has directly influenced and participated in approximately 1.5 billion dollars in acquisition events.

Additionally, he has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Mr. Ferrari was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. He is also the co-founder of Transaortic, an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. He was also the Executive Chairman of SentreHeart where he led the acquisition to Atricure for $300Mill.

Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.

Suha Jhaveri, Member of Board of Directors

Ms. Jhaveri is presently the Chief Commercial Officer and Head of Business Development of Leyden Labs. Previously she was VP, Market Development of Vir Biotechnology, Global Commercial Leader and New Product Planning for Ultragenyx Pharmaceuticals. Prior to that, she was the Chief Operating Officer of OBMedical Company, and held a variety of executive positions with biotech and tech companies as well as working as a consultant for Boston Consulting Group. She holds an MBA from Harvard, a MA in Economic Development from the University of Sussex, and a BA in International Relations from Stanford University.

Invest in Evren and Create a Positive Social Impact

Our team envisions a future in which those suffering from Post-Traumatic Stress Disorder can be treated effectively.

We invite you to participate in our equity crowdfunding campaign. Please visit our StartEngine raise page, where you can learn more about our mission to improve countless lives and bring a happier, healthier future to those in need.

72 views0 comments

Recent Posts

See All


bottom of page